Proactive Investors - Run By Investors For Investors

Midatech Phama signs US co-promotion deal for cancer care product

NeutraSal is prescribed for Xerostomia, also known as dry mouth syndrome, which is a common side-effect of cancer treatment
word cancer under the looking glass
The company is broadening its portfolio, which brings with it synergies

Midatech Pharma Plc (LON:MTPH) said its US arm has signed a deal that gives it the exclusive right to promote a cancer care product in the US.

It has inked a co-promotion agreement with Bausch Health Companies to for NeutraSal to oncology customers in the US.

In exchange for its efforts, Midatech will receive a percentage of the net sales. The financial terms of the agreement are undisclosed. 

Common cancer side-effect

The product is prescribed for Xerostomia, also known as dry mouth syndrome, which is a common side-effect of cancer treatment.

"NeutraSal provides oncology professionals with an effective therapy for patients suffering from Xerostomia, which can be a painful and debilitating side effect of certain cancer therapies,” said David Benharris, president of Midatech’s US business. 

He pointed synergies will be derived by selling a broader range of oncology products. “The addition of NeutraSal to our portfolio appreciably enhances our offering of effective treatment options to provide continuity of care for patients suffering from the side effects of cancer therapies," he explained.

View full MTPH profile View Profile

Midatech Pharma PLC Timeline

Related Articles

Enzymes under a microscope
April 29 2019
The Florida company applies its proprietary C1 gene expression platform to speed up the development of biologic vaccines, drugs at flexible commercial scales
Cancer cells
June 27 2018
The Nottingham-based privately-owned company has made an impressive fist of developing the OMIS (Opto-magnetic Imaging Spectroscopy) cancer detection system
scientist at petrie dish
Here we take a closer look at Midatech Pharma PLC (LON:MTPH)

© Proactive Investors 2019

Proactive Investors Australia PTY LTD ACN:132787654 ABN:19132787654.

Market Indices, Commodities and Regulatory News Headlines copyright © Morningstar. Data delayed 15 minutes unless otherwise indicated. Terms of use